M&A analysis: bolt-ons for J&J and Bristol
The biggest oncology buy of the quarter concerned the prostate cancer player Halda.
Chimerix's cancer transformation
US approval could mark the company's graduation to oncology.
Biocytogen and PTK7 remain hot
First-in-human trial initiations include Biocytogen's DM002 and Day One's DAY301.
FDA green and red lights: April 2024
A tumour-agnostic label for Enhertu leads April’s US oncology approvals.
A new dawn for tovorafenib
The FDA's tough stance notwithstanding, Ojemda gets an accelerated green light.
